QQ客服 官方微博 反馈留言

浏览/检索结果: 共12条，第1-10条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 期刊论文 JOURNAL OF HEPATOLOGY, 2019, 卷号: 70 作者:  Gong, Guozhong;  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun 收藏  |  浏览/下载：56/0  |  提交时间：2019/12/05 All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文 作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang 收藏  |  浏览/下载：44/0  |  提交时间：2019/12/05 THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文 作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang 收藏  |  浏览/下载：34/0  |  提交时间：2019/12/05 All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文 作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang 收藏  |  浏览/下载：36/0  |  提交时间：2019/12/05 THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文 作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang 收藏  |  浏览/下载：32/0  |  提交时间：2019/12/05 All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文 作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang 收藏  |  浏览/下载：29/0  |  提交时间：2019/12/05 Efficacy and Safety of All-Oral, 12-Week Ravidasvir Plus Ritonavir-Boosted Danoprevir and Ribavirin in Treatment-Naive Non-Cirrhotic HCV Genotype 1 Patients : Results from a Phase 2/ 3 Clinical Trial in China 期刊论文 HEPATOLOGY, 2018, 卷号: 68 作者:  Wei, Lai;  Xu, Xiaoyun;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Jifang 收藏  |  浏览/下载：21/0  |  提交时间：2019/12/05 Efficacy and Safety of All-Oral, 12-Week Ravidasvir Plus Ritonavir-Boosted Danoprevir and Ribavirin in Treatment-Naive Non-Cirrhotic HCV Genotype 1 Patients : Results from a Phase 2/ 3 Clinical Trial in China 会议论文 作者:  Wei, Lai;  Xu, Xiaoyun;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Jifang 收藏  |  浏览/下载：11/0  |  提交时间：2019/12/05 Efficacy and Safety of All-Oral, 12-Week Ravidasvir Plus Ritonavir-Boosted Danoprevir and Ribavirin in Treatment-Naive Non-Cirrhotic HCV Genotype 1 Patients : Results from a Phase 2/ 3 Clinical Trial in China 会议论文 作者:  Wei, Lai;  Xu, Xiaoyun;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Jifang 收藏  |  浏览/下载：11/0  |  提交时间：2019/11/19 In-hospital outcomes of dual loading antiplatelet therapy in patients 75 years and older with acute coronary syndrome undergoing percutaneous coronary intervention: Findings from the CCC-ACS (Improving Care for Cardiovascular Disease in China-acute coronary syndrome) project 期刊论文 Journal of the American Heart Association, 2018, 卷号: 7 作者:  Zhao, Guanqi;  Zhou, Mengge;  Ma, Changsheng;  Huo, Yong;  Smith, Sidney C. 收藏  |  浏览/下载：60/0  |  提交时间：2019/11/26 Acute coronary syndrome  Antiplatelet therapy  Elderly  Loading dose  Percutaneous coronary intervention